chronic obstructive pulmonary disease (COPD)

AZ
Biotech

AstraZeneca pens $2.1B deal for challenger to Merck’s Ohtuvayre

AstraZeneca is paying $200 million upfront for ex-China rights to a late-phase challenger to Merck & Co.’s COPD drug Ohtuvayre.
Nick Paul Taylor Jul 8, 2026 5:00am
Lung

AstraZeneca’s faith in IL-33 blocker pays off with new ph. 3 win

Apr 20, 2026 7:22am
Metallic arrow symbols illuminated by blue and magenta lights forming a graph on blue and magenta background

Connect’s Dupixent rival hits the mark in phase 3 eczema trial

Mar 30, 2026 9:32am
On target clinical trial success bullseye score

AstraZeneca’s COPD hits breathe life into class rocked by flops

Mar 27, 2026 5:58am
Brett Giroir

Sanofi backs Altesa's $75M series B to bankroll rhinovirus study

Feb 19, 2026 7:00am
China export industry and global supply chain Cargo airplane flying over logistic containers

AirNexis swoops in with $200M series A for COPD asset

Jan 9, 2026 11:01am